Shares of Sarepta Therapeutics (SRPT) surged approximately 47% in after-hours trading on NasdaqGS after the U.S. Food and Drug Administration recommended lifting the voluntary hold on the company's gene therapy, Elevidys, for ambulatory patients with Duchenne Muscular Dystrophy (DMD). Following an investigation into the recent death of an 8-year-old patient, the FDA concluded that the incident was not related to the gene therapy product itself.
The FDA said it will continue to work with the sponsor regarding non ambulatory patients, which remains subject to a voluntary hold, following two deaths.
For comments and feedback contact: editorial@rttnews.com
Business News
April 24, 2026 15:15 ET Economics news flow was relatively light this week even as the conflict in the Middle East continued, raising concerns for policymakers. In the U.S., spending data, initial jobless claims and pending home sales were the highlights. Business confidence in the biggest euro area economy was in focus in Europe. Inflation data from Japan gained attention in Asia.